Blueprint Medicines (BPMC) Misses Q3 EPS by 37c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.00), $0.37 worse than the analyst estimate of ($1.63).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Westinghouse said to seek over $50 billion valuation in planned IPO
• HP shares slide as tech giant forecasts 2027 PC market slump